Seven participants attended the live meeting and discussed the following agenda items: (1) Identification and prioritization of unmet needs of patients with COPD (2) Discussion of prototypical patients who may benefit from nebulized LABA therapy and (3) Derivation of guiding principles to help clinicians decide if nebulized LABA therapy is appropriate for their patients. 14 MethodsĪ roundtable meeting was convened with the purpose of discussing the role of nebulized long-acting beta2-agonist (LABA) therapy in patients with COPD. 4-7 Furthermore, medication adherence is poor, 8 device selection may not be thoroughly individualized to patient needs, 9 physical and cognitive functions that enable patients to effectively self-manage decline with age, 10-13 and there is a lack of disease modifying pharmacological / biological agents in COPD. Smoking continues to be a major contributor to the onset and progression of the disease, 3 which is often underdiagnosed and undertreated. 1,2 There are currently many unmet medical needs in the care of patients with COPD. doi: Introductionĭespite advances in medical therapy and the availability of clinical practice guidelines for chronic obstructive pulmonary disease (COPD), the trajectory of the disease is unwavering when considering exacerbations, hospitalizations, and mortality. Guiding principles for the use of nebulized long-acting beta2-agonists in patients with COPD: An expert panel consensus. The sponsor had no role in the development or approval of this manuscript.Ībbreviations: chronic obstructive pulmonary disease, COPD long-acting beta2-agonist, LABA peak inspiratory flow rate, PIFR dry powder inhaler, DPI confidence interval, CI peak inspiratory flow, PIF Global initiative for chronic Obstructive Lung Disease, GOLD long-acting beta2-agonists, LABA Centers for Medicare & Medicaid Services, CMS Hospital Readmissions Reduction Program, HRRP short-acting beta2-agonists, SABA pressurized metered dose inhaler, pMDI soft-mist inhaler, SMI forced expiratory volume in 1 second, FEV 1 forced vital capacity, FVC inspiratory capacity, IC long-term care, LTCĬitation: Wise RA, Acevedo RA, Anzueto AR, et al. Running Head: Nebulized LABA Therapy for COPDįunding Support:Funding for the live roundtable meeting held on Augin Boston, Massachusetts and medical writing support was provided by Sunovion Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |